PROJECTS

COLOPLAST, CMCR II CLEAN ROOM MODIFICATION

This remodulation project comprises architectural and finishing works inside of the approx. 3,100 m² clean rooms as well as installation of air handling units and utility supply lines on the 3,100 m² technical floor above the clean rooms.

Read More »

COLOPLAST, CMCR I CLEAN ROOM MODIFICATION

Shortly after the handing-over of Coloplast’s first facility in Costa Rica (CMCR I) in the beginning of 2021, a project comprising remodulation and utility extension of the clean rooms was initiated, in order to accommodate new requirements to the production machines and utilization of the clean rooms.

Read More »

COLOPLAST, CMCR II

As Full-Service Client Consultant for the project, Aqvila are responsible for all design services in connection with the conceptual design, detailed design, necessary permit applications, tender documentation as well as general project management.

Read More »

RADIOMETER, RSOL II

Currently, Radiometer Solutions, global leader in the development, production and distribution of technologically advanced blood analyzers in the field of gasometry, electrolytes and metabolites, have an production facility (RSOL I) of approx. 3,500 m2 in Poland. After the RSOL II expansion, the total production facility will reach approx. 18,460 m2 and the number of employees will increase from approx. 400 people to approx. 600 people in 2020.

Read More »

NCC DANMARK, KRONLØBSØEN

Danish contractor NNC Danmark was in April 2019 awarded the Design-Build & Turnkey contract for the apartment complex Kronløbsøen in Copenhagen Nordhavn, Denmark – a link across Kronløbsbassinet featuring bridge connections to both Århusgadekvartereret/fortkaj and sundmolen.

Read More »

NOVO NORDISK, LMSB

In Algeria, it is estimated that nearly 2 million Algerian citizens suffer from diabetes. A figure that is expected to rise to more than 3 million cases by 2040. Consequently, Novo Nordisk made a decision to invest in a new production facility. The facility is expected to start the production of insulin pens and other medicines for diabetes in August 2019, after having faced a number of constraints related to the purchase of the land and lack of water and electricity.

Read More »

This website uses cookies to ensure you the best experience on our website. By using the website you accept the use of cookies.